New and Future Drug Development for Gastroesophageal Reflux Disease

作者：Maradey Romero Carla; Fass Ronnie^*

来源：Journal of Neurogastroenterology and Motility, 2014, 20(1): 6-16.

DOI：10.5056/jnm.2014.20.1.6

• Erosive esophagitis
• Gastroesophageal reflux
• Heartburn
• Proton pump inhibitors

Medical therapy remains the most popular treatment for gastroesophageal reflux disease (GERD). Whilst interest in drug development for GERD has declined over the last few years primarily due to the conversion of most proton pump inhibitor (PPI)'s to generic and over the counter compounds, there are still numerous areas of unmet needs in GERD. Drug development has been focused on potent histamine type 2 receptor antagonist's, extended release PPI's, PPI combination, potassium-competitive acid blockers, transient lower esophageal sphincter relaxation reducers, prokinetics, mucosal protectants and esophageal pain modulators. It is likely that the aforementioned compounds will be niched for specific areas of unmet need in GERD, rather than compete with the presently available anti-reflux therapies.

• 出版日期2014-1